Lycera Secures $20,999,999 New Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    2800 Plymouth Rd NCRC Building 26 Ann Arbor, MI 48109
  • Company Description
    Lycera is an early-stage pharmaceutical company developing first-in-class drugs to treat immune disorders. Lycera’s technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing.
  • M&A Terms
  • Venture Investor

Trending on Xconomy